Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning
How Novo Nordisk Built a Moat on GLP-1 Patents and Scale
In this episode of Business Strategy Talks, Lucas and Luna explore how Novo Nordisk built an economic moat around its GLP-1 diabetes and weight-loss drugs. They break down the specific patent barriers, manufacturing scale advantages, and clinical data that have made Ozempic and Wegovy so hard to replicate. With over 50 million patients and a market cap exceeding $600 billion, Novo Nordisk has become one of the most valuable companies in Europe. Lucas explains why the moat isn't just about patents—it's about the decades of investment in peptide chemistry, the controlled supply chain…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.